Fresenius SE Gross Profit 2016-2023 | FSNUY

Fresenius SE annual/quarterly gross profit history and growth rate from 2016 to 2023. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Fresenius SE gross profit for the quarter ending September 30, 2023 was $1.384B, a 49.18% decline year-over-year.
  • Fresenius SE gross profit for the twelve months ending September 30, 2023 was $9.479B, a 17.94% decline year-over-year.
  • Fresenius SE annual gross profit for 2022 was $11.3B, a 7.37% decline from 2021.
  • Fresenius SE annual gross profit for 2021 was $12.199B, a 3.52% increase from 2020.
  • Fresenius SE annual gross profit for 2020 was $11.784B, a 1.68% increase from 2019.
Fresenius SE Annual Gross Profit
(Millions of US $)
2022 $11,300
2021 $12,199
2020 $11,784
2019 $11,590
2018 $11,614
2017 $11,841
2016 $10,101
2015 $9,476
Fresenius SE Quarterly Gross Profit
(Millions of US $)
2023-09-30 $1,384
2023-06-30 $2,544
2023-03-31 $2,695
2022-12-31 $2,855
2022-09-30 $2,724
2022-06-30 $2,850
2022-03-31 $2,871
2021-12-31 $3,106
2021-09-30 $2,975
2021-06-30 $3,154
2021-03-31 $2,963
2020-12-31 $3,088
2020-09-30 $2,927
2020-06-30 $2,809
2020-03-31 $2,960
2019-12-31 $3,016
2019-09-30 $2,855
2019-06-30 $2,875
2019-03-31 $2,844
2018-12-31 $2,997
2018-09-30 $2,784
2018-06-30 $2,960
2018-03-31 $2,874
2017-12-31 $3,139
2017-09-30 $2,928
2017-06-30 $2,905
2017-03-31 $2,870
2016-12-31 $2,698
2016-09-30 $2,554
2016-06-30 $2,487
2016-03-31 $2,362
2015-12-31 $7,951
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $16.733B $24.011B
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
Stock Name Country Market Cap PE Ratio
Quest Diagnostics (DGX) United States $15.759B 16.29
DaVita (DVA) United States $11.818B 14.68
Encompass Health (EHC) United States $8.593B 22.00
Chemed (CHE) United States $8.450B 26.19
Elanco Animal Health (ELAN) United States $8.367B 21.70
Option Care Health (OPCH) United States $5.046B 19.10
RadNet (RDNT) United States $4.290B 89.34
Amedisys (AMED) United States $3.162B 22.40
LifeStance Health (LFST) United States $2.221B 0.00
Astrana Health (ASTH) United States $2.135B 28.86
Addus HomeCare (ADUS) United States $1.805B 25.82
U.S Physical Therapy (USPH) United States $1.554B 41.57
Pennant (PNTG) United States $0.695B 36.71
Aveanna Healthcare Holdings (AVAH) United States $0.543B 0.00
Atai Life Sciences (ATAI) Germany $0.280B 0.00
Daxor (DXR) United States $0.045B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.028B 0.00
ATI Physical Therapy (ATIP) United States $0.022B 0.00
Psychemedics (PMD) United States $0.015B 0.00
Ontrak (OTRK) United States $0.013B 0.00
Novo Integrated Sciences (NVOS) United States $0.009B 0.00
IMAC Holdings (BACK) United States $0.004B 0.00